2020 was a challenging year for Medistim. As the COVID-19 pandemic escalated, the need to treat COVID-19 patients took priority over elective surgeries.
Following a good start to the year, Medistim experienced a significant impact on operations in the first months of the pandemic. However, due to a solid revenue base and good pipeline activity throughout the second half of the year, overall sales for the year ended unchanged from 2019. The Medistim Group’s sales for the full year 2020 ended at NOK 363.1 million (NOK 363.7 million). Currency neutral, sales declined 6.1%.
Read the full report here: